Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Assets (2016 - 2025)

Historic Assets for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $137.0 million.

  • Kyntra Bio's Assets fell 4818.34% to $137.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.0 million, marking a year-over-year decrease of 4818.34%. This contributed to the annual value of $214.5 million for FY2024, which is 4934.82% down from last year.
  • Latest data reveals that Kyntra Bio reported Assets of $137.0 million as of Q3 2025, which was down 4818.34% from $178.1 million recorded in Q2 2025.
  • Over the past 5 years, Kyntra Bio's Assets peaked at $850.5 million during Q3 2021, and registered a low of $137.0 million during Q3 2025.
  • Over the past 5 years, Kyntra Bio's median Assets value was $515.1 million (recorded in 2023), while the average stood at $496.2 million.
  • In the last 5 years, Kyntra Bio's Assets surged by 474.1% in 2021 and then crashed by 5484.36% in 2025.
  • Quarter analysis of 5 years shows Kyntra Bio's Assets stood at $773.8 million in 2021, then fell by 21.16% to $610.1 million in 2022, then plummeted by 30.58% to $423.5 million in 2023, then tumbled by 49.35% to $214.5 million in 2024, then plummeted by 36.13% to $137.0 million in 2025.
  • Its Assets stands at $137.0 million for Q3 2025, versus $178.1 million for Q2 2025 and $165.2 million for Q1 2025.